<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397707</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-338-1126</org_study_id>
    <secondary_id>2015-000342-30</secondary_id>
    <nct_id>NCT02397707</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</brief_title>
  <official_title>A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and
      tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal
      hepatic function, moderate hepatic impairment and severe hepatic impairment. Participants in
      the healthy control group will be matched to participants with impaired hepatic function by
      gender, age (± 10 years), and body mass index (± 15%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2015</start_date>
  <completion_date type="Actual">March 4, 2016</completion_date>
  <primary_completion_date type="Actual">March 4, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast</measure>
    <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration. Data presented are unadjusted geometric means and confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of Voxilaprevir: AUCinf</measure>
    <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time. Data presented are unadjusted geometric means and confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of Voxilaprevir: Cmax</measure>
    <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of drug.Data presented are unadjusted geometric means and confidence intervals.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxilaprevir</intervention_name>
    <description>100 mg tablet administered orally</description>
    <arm_group_label>Moderate Hepatic Impaired</arm_group_label>
    <arm_group_label>Severe Hepatic Impaired</arm_group_label>
    <other_name>GS-9857</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  All individuals:

               -  Screening laboratory values within defined thresholds for group

               -  Use of two effective contraception methods if female of childbearing potential or
                  sexually active male

          -  For individuals with moderate hepatic impairment:

               -  Diagnosis of chronic (&gt; 6 months) hepatic impairment

               -  Score on the Child-Pugh-Turcotte (CPT) scale of 7-9 at screening (Child Pugh
                  Class B).

          -  For individuals with severe hepatic impairment:

               -  Diagnosis of chronic (&gt; 6 months) hepatic impairment

               -  Score on the CPT scale of 10-15 at screening (Child Pugh Class C)

          -  For individuals with normal hepatic function:

               -  Hepatitis C Virus (HCV) antibody and hepatitis B surface antigen negative

        Key Exclusion Criteria:

          -  All individuals:

               -  Pregnant or nursing female or male with pregnant female partner

               -  HIV infection

               -  History of clinically significant illness or any other medical disorder that may
                  interfere with the individual's treatment, assessment or compliance with the
                  protocol

          -  For individuals with moderate or severe hepatic impairment:

               -  Active HCV infection

               -  Current hepatic encephalopathy

               -  Variceal bleeding in the last 6 months unless banded

               -  Prior placement of a portosystemic shunt

               -  History of hepatorenal or hepatopulmonary syndrome

               -  Spontaneous bacterial peritonitis currently or within the last 6 months

               -  Hospitalization within the last 2 months related to cirrhosis

               -  Confirmed hypotension

               -  Suspicion of hepatocellular carcinoma

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lawitz E, Marbury T, Kirby BJ, Au NT, Mathias A, Stamm LM, et al. The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, A Pan-Genotypic HCV NS3/4A Protease Inhibitor [Abstract FRI-167]. J Hepatology 2016:S613-S4.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <results_first_submitted>March 4, 2020</results_first_submitted>
  <results_first_submitted_qc>March 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2020</results_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States, Germany, and New Zealand. The first participant was screened on 24 March 2015. The last study visit occurred on 04 March 2016.</recruitment_details>
      <pre_assignment_details>54 participants were screened. 33 participants were enrolled, 14 participants with normal hepatic function, 10 with Moderate Hepatic Impairment (MHI), and 9 with Severe Hepatic Impairment (SHI). Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Moderate Hepatic Impairment (MHI)</title>
          <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Severe Hepatic Impairment (SHI)</title>
          <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set included all participants who took at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Moderate Hepatic Impairment (MHI)</title>
          <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Severe Hepatic Impairment (SHI)</title>
          <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="9.8"/>
                    <measurement group_id="B2" value="55" spread="6.7"/>
                    <measurement group_id="B3" value="55" spread="7.0"/>
                    <measurement group_id="B4" value="54" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="2.21"/>
                    <measurement group_id="B2" value="27.6" spread="3.90"/>
                    <measurement group_id="B3" value="28.4" spread="3.86"/>
                    <measurement group_id="B4" value="27.8" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast</title>
        <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration. Data presented are unadjusted geometric means and confidence intervals.</description>
        <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>PK Analysis Set included all enrolled participants who took at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value reported by the PK laboratory for the corresponding analyte. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (MHI)</title>
            <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment (SHI)</title>
            <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for MHI)</title>
            <description>Normal Hepatic Function (matched control for MHI) included participants that served as controls for participants with MHI.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Controls for SHI)</title>
            <description>Normal hepatic function (matched controls for SHI) included participants that served as controls for participants with SHI.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast</title>
          <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration. Data presented are unadjusted geometric means and confidence intervals.</description>
          <population>PK Analysis Set included all enrolled participants who took at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value reported by the PK laboratory for the corresponding analyte. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2058.5" lower_limit="1034" upper_limit="4098.1"/>
                    <measurement group_id="O2" value="3872.5" lower_limit="2173.1" upper_limit="6901.2"/>
                    <measurement group_id="O3" value="500.1" lower_limit="307" upper_limit="814.6"/>
                    <measurement group_id="O4" value="601.2" lower_limit="372.8" upper_limit="969.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An analysis of variance (ANOVA) appropriate for a parallel design was fitted to the natural logarithmic transformation of voxilaprevir AUClast. A 90% confidence interval (CI) was constructed for the geometric least squares mean (GLSM) ratio of AUClast for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least-Square Mean (GLSM)Ratio%</param_type>
            <param_value>411.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>214.72</ci_lower_limit>
            <ci_upper_limit>789.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANOVA appropriate for a parallel design was fitted to the natural logarithmic transformation of voxilaprevir AUClast. A 90% CI was constructed for the GLSM ratio of AUClast for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>644.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>364.67</ci_lower_limit>
            <ci_upper_limit>1137.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter of Voxilaprevir: AUCinf</title>
        <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time. Data presented are unadjusted geometric means and confidence intervals.</description>
        <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>Participants in the PK Analysis Set were analyzed. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (MHI)</title>
            <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment (SHI)</title>
            <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for MHI)</title>
            <description>Normal Hepatic Function (matched control for MHI) included participants that served as controls for participants with MHI.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Controls for SHI)</title>
            <description>Normal hepatic function (matched controls for SHI) included participants that served as controls for participants with SHI.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Voxilaprevir: AUCinf</title>
          <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time. Data presented are unadjusted geometric means and confidence intervals.</description>
          <population>Participants in the PK Analysis Set were analyzed. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2227.1" lower_limit="1122" upper_limit="4420.7"/>
                    <measurement group_id="O2" value="4107.5" lower_limit="2331.7" upper_limit="7235.7"/>
                    <measurement group_id="O3" value="557.8" lower_limit="351.8" upper_limit="884.6"/>
                    <measurement group_id="O4" value="685" lower_limit="426.1" upper_limit="1101.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An ANOVA appropriate for parallel design was fitted to the natural logarithmic transformation of voxilaprevir AUCinf. A 90% CI was constructed for the GLSM ratio of AUClast for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>399.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>210.89</ci_lower_limit>
            <ci_upper_limit>755.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANOVA appropriate for parallel design was fitted to the natural logarithmic transformation of voxilaprevir AUCinf. A 90% CI was constructed for the GLSM ratio of AUCinf for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>599.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>342.36</ci_lower_limit>
            <ci_upper_limit>1050.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter of Voxilaprevir: Cmax</title>
        <description>Cmax is defined as the maximum observed plasma concentration of drug.Data presented are unadjusted geometric means and confidence intervals.</description>
        <time_frame>0 (pre-dose ≤ 5 minutes), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>Participants in the PK Analysis Set were analyzed. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (MHI)</title>
            <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment (SHI)</title>
            <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for MHI)</title>
            <description>Normal Hepatic Function (matched control for MHI) included participants that served as controls for participants with MHI.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Controls for SHI)</title>
            <description>Normal hepatic function (matched controls for SHI) included participants that served as controls for participants with SHI.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter of Voxilaprevir: Cmax</title>
          <description>Cmax is defined as the maximum observed plasma concentration of drug.Data presented are unadjusted geometric means and confidence intervals.</description>
          <population>Participants in the PK Analysis Set were analyzed. Five of the same participants with normal hepatic function served as matched controls for the MHI and SHI Arms/Groups.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.7" lower_limit="85.2" upper_limit="422.3"/>
                    <measurement group_id="O2" value="370.8" lower_limit="183.6" upper_limit="749"/>
                    <measurement group_id="O3" value="56.1" lower_limit="38.2" upper_limit="82.2"/>
                    <measurement group_id="O4" value="51.9" lower_limit="35.1" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An ANOVA appropriate was fitted to the natural logarithmic transformation of voxilaprevir Cmax. A 90% CI was constructed for the GLSM ratio of AUClast for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>338.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>168.96</ci_lower_limit>
            <ci_upper_limit>677.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANOVA appropriate was fitted to the natural logarithmic transformation of voxilaprevir Cmax. A 90% CI was constructed for the GLSM ratio of AUClast for the comparison groups using two 1-sided tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>713.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>384.07</ci_lower_limit>
            <ci_upper_limit>1327.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date up to 31 days</time_frame>
      <desc>Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Moderate Hepatic Impairment (MHI)</title>
          <description>Participants with moderate hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Severe Hepatic Impairment (SHI)</title>
          <description>Participants with severe hepatic impairment received single dose of voxilaprevir 100 mg tablet orally on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

